LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PGEN
Precigen, Inc.
There isn't enough reported data to score PGEN yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PGEN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
PGEN's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over PGEN in the historical PE scenario, which offers more potential upside but is not a forecast.
PGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.2x | $4.66 | — |
| Cheap | 7.9x | $0.55 | -88% |
| Fair | 9.5x | $0.66 | -86% |
| Expensive | 14x | $0.98 | -79% |
| Current | 67x | $4.66 | — |
Historical ranges are pointers, not guarantees.
PGEN's PE is 67x, but its earnings don't support one, so it isn't a reliable read right now.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect PGEN to return to profit, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PGEN on earnings, with more consistent year-over-year improvement.
PGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.65 | +829% |
| Q3 2026 | $0.07 | +$1.45 |
| Q2 2026 | -$1.07 | -$0.66 |
| Q1 2026 | -$1.21 | -$0.66 |
| Q4 2025 | -$1.37 | -$0.90 |
| Q3 2025 | -$1.38 | -$0.83 |
| Q2 2025 | -$0.41 | +$0.13 |
| Q1 2025 | -$0.55 | -$0.16 |
| Q4 2024 | -$0.47 | -$0.08 |
PGEN has returned to profit: it earned $0.07 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
PGEN has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus up 3,906% for PGEN.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
PGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $1.8M | -39% |
| Q1 2023 | $1.9M | -94% |
| Q4 2022 | $1.8M | -93% |
| Q3 2022 | $16.7M | -22% |
| Q2 2022 | $2.9M | -91% |
| Q1 2022 | $32M | +31% |
| Q4 2021 | $24.2M | +25% |
| Q3 2021 | $21.6M | -8.6% |
PGEN's revenue is growing: $74M last quarter, up 3906% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 52% | N/A |
| Q2 2026 | 41% | N/A |
| Q1 2026 | -26% | N/A |
| Q2 2023 | -1154% | -255 points |
| Q1 2023 | -1231% | -1171 points |
| Q4 2022 | -1257% | -1154 points |
| Q3 2022 | -46% | +93 points |
| Q2 2022 | -898% | -838 points |
PGEN has the edge over LLY on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
PGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.4M | +$40.9M |
| Q2 2026 | -$18.2M | +$1.7M |
| Q1 2026 | -$44.1M | -$27.1M |
| Q4 2025 | -$23.5M | -$14.2M |
| Q3 2025 | -$29.5M | -$5.8M |
| Q2 2025 | -$19.9M | +$5.5M |
| Q1 2025 | -$16.9M | +$1.5M |
| Q4 2024 | -$9.3M | +$7.5M |
PGEN has burned cash in almost every quarter: −$74M over the past year, against −$76M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +7.5M shares |
| 1 year | +37% | +114M shares |
| 3 years | +69% | +173M shares |
| 5 years | +112% | +222M shares |
| Available history | +173% | +267M shares |
PGEN has 421M diluted shares, up 37% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PGEN Net Leverage
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 23.8 | Neutral |
PGEN's weekly RSI is 43 (neutral) and its Stochastic is 24 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over PGEN on valuation relative to its sector.
PGEN PE vs Healthcare Sector
| Metric | PGEN | Sector median | Relative |
|---|---|---|---|
| PE | 67x | 26x | 158% above |
| PE % | 100 | 29 | 71 pts above |
PGEN is trading at 67x earnings, a 158% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PGEN on trend strength, trading above more of its moving averages.
PGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.59 | 29% below |
| 20 week MA | $6.48 | 28% below |
| 50 week MA | $5.10 | 8.6% below |
| 100 week MA | $3.68 | 27% above |
| 200 week MA | $2.48 | 88% above |
PGEN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 88% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PGEN on returns for 2026, with the stronger performance.
PGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.74 | $10.0 | +75% |
| 2021 | $10.0 | $4.10 | -59% |
| 2022 | $4.10 | $1.40 | -66% |
| 2023 | $1.40 | $1.34 | -4.3% |
| 2024 | $1.34 | $0.73 | -46% |
| 2025 | $0.73 | $4.16 | +470% |
| 2026 YTD | $4.16 | $4.66 | +12% |
PGEN's yearly returns have swung widely, from +470% in 2025 to −66% in 2022. It's up 12% so far in 2026.